On May 30, 2019 Orion Biotechnology Canada Ltd., a developer of novel medical treatments, reported their Chief Medical Officer, Ian McGowan MD Ph.D. FRCP, will be presenting at the ASCO (Free ASCO Whitepaper) meeting which is being held in Chicago (May 31st to June 3, 2019; View Source) (Press release, Orion Biotechnology, MAY 30, 2019, View Source [SID1234536714]). His talk will be in the Gastrointestinal (Colorectal) cancer track and will focus on the surveillance and management of anal intraepithelial neoplasia in HIV and non-HIV infected patients. In his previous position, as a Professor of Medicine at the University of Pittsburgh Medical School, his laboratory undertook research to characterize the prevalence of anal human papillomavirus (HPV) infection in men who have sex with men (MSM) and transgender women. In the MTN-017 study which was conducted in the US, Peru, Thailand, and South Africa. Dr. McGowan’s laboratory showed that approximately 93% of MSM had evidence of anal HPV infection which is linked to the development of anal dysplasia and anal cancer (Cranston et al. Int J STD AIDS 2019).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Despite increased availability of highly efficacious HPV vaccines, there is a large pool of individuals who have already acquired anal HPV infection and are at risk of developing epithelial dysplasia and in some cases cancer. Unfortunately, this risk is significantly increased when there is co-infection with HIV. These patients should undergo regular surveillance to recognize and treat anal dysplasia to avoid progression to anal cancer," said Dr. McGowan.

Orion Biotechnology has an active preclinical program focused on the treatment of gastrointestinal cancers with our lead compound, OB-002, and plans to submit an IND to support Phase 1 clinical trials in 2020.

On May 30, 2019 Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported that it will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6, 2019, in New York (Press release, Neurocrine Biosciences, MAY 30, 2019, View Source [SID1234536713]). Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

On May 30, 2019 Eli Lilly and Company (NYSE: LLY) reported that it will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Joshua Smiley, senior vice president and Lilly’s chief financial officer, will participate in a fireside chat at 1:20 p.m., Pacific Time (Press release, Eli Lilly, MAY 30, 2019, View Source [SID1234536712]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On May 30, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will present at the Jefferies Annual Global Healthcare Conference in New York on Thursday, June 6th at 2:00 p.m. ET/ 11:00 a.m. PT. Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer will present a corporate overview at the conference (Press release, Mirati, MAY 30, 2019, View Source [SID1234536711]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and made available through the "Investors" section of www.mirati.com, and replays will be made available for 90 days following the events.

On May 30, 2019 Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, reported the initiation of the Phase 1b expansion stage of its ongoing Phase 1 study evaluating the investigational agent TP-0903, an AXL receptor tyrosine kinase (RTK) inhibitor, in patients with advanced solid tumors (Press release, Tolero Pharmaceuticals, MAY 30, 2019, View Source [SID1234536710]). The maximum tolerated dose (MTD) of TP-0903 was established during the Phase 1a portion of the study, allowing the study to advance to the Phase 1b stage. AXL inhibition by TP-0903 has shown to have anti-tumor activity and to reverse mesenchymal phenotype, leading to immune surveillance inhibition in preclinical models resistant to targeted agents including immunotherapeutics.1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1b stage of the study will enroll additional patients with specific solid tumor types, including advanced solid tumors with progressive disease post immunotherapy, EGFR positive non-small cell lung cancer progressed following TKI therapies, colorectal carcinoma (BRAF-, KRAS-, or NRAS-mutated), platinum refractory or resistant recurrent ovarian carcinoma, and BRAF-mutated melanoma progressed following immunotherapy or combination BRAF/MEK inhibitor.

"This milestone marks an important step forward in the clinical development of TP-0903 as a potential treatment option for patients with advanced solid tumors," said David J. Bearss, Ph.D., Chief Executive Officer of Tolero Pharmaceuticals, Inc. "We believe this study may further our understanding of the anti-tumor activity of TP-0903 in these tumor types."

The primary outcome measures of the interventional, open-label, non-randomized, dose-escalation study is to assess the incidence of dose-limiting toxicities and treatment emergent adverse events of oral TP-0903 administered once daily in patients with advanced solid tumors. Secondary outcome measures include pharmacokinetics, activity on predictive biomarkers and objective response rate of TP-0903. The Phase 1b stage of the study is expected to enroll up to 20 patients in each of the five additional cohorts, for a total of up to 100 additional patients enrolled. Ten patients in each of the five expansion cohorts will undergo pre- and post-dose tumor biopsies.

The study is being conducted in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT02729298).

About TP-0903
TP-0903 is an investigational oral AXL receptor tyrosine kinase (RTK) inhibitor under evaluation in a Phase 1/2 study in patients with CLL/SLL (NCT03572634) and a Phase 1b study in patients with advanced solid tumors (NCT02729298). Tolero is exploring parallel clinical development paths for TP-0903 in both solid and hematologic malignancies.

About AXL Kinase
AXL belongs to the TAM (Tyro3, AXL and Mer) family of receptor tyrosine kinases and is overexpressed in many human cancers.1 It plays a key role in tumor cell proliferation, survival, metastasis, cellular adhesion and avoidance of the immune response. The overexpression of AXL is associated with a poor patient prognosis and drug resistance.2